897 related articles for article (PubMed ID: 27876247)
1. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW
Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Noble PW; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Lancaster L; Lederer DJ; Leff JA; Nathan SD; Pereira CA; Swigris JJ; Valeyre D; King TE
Eur Respir J; 2016 Jan; 47(1):243-53. PubMed ID: 26647432
[TBL] [Abstract][Full Text] [Related]
7. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Glasscock KF; King TE; Lancaster L; Lederer DJ; Lin Z; Pereira CA; Swigris JJ; Valeyre D; Noble PW; Wells AU
Thorax; 2016 May; 71(5):429-35. PubMed ID: 26968970
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.
Lederer DJ; Bradford WZ; Fagan EA; Glaspole I; Glassberg MK; Glasscock KF; Kardatzke D; King TE; Lancaster LH; Nathan SD; Pereira CA; Sahn SA; Swigris JJ; Noble PW
Chest; 2015 Jul; 148(1):196-201. PubMed ID: 25856121
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
[TBL] [Abstract][Full Text] [Related]
12. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
[TBL] [Abstract][Full Text] [Related]
14. Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis.
Fisher M; Nathan SD; Hill C; Marshall J; Dejonckheere F; Thuresson PO; Maher TM
J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S17-S24. PubMed ID: 28287347
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.
Kim ES; Keating GM
Drugs; 2015 Feb; 75(2):219-30. PubMed ID: 25604027
[TBL] [Abstract][Full Text] [Related]
16. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
Glassberg MK; Nathan SD; Lin CY; Morgenthien EA; Stauffer JL; Chou W; Noble PW
Adv Ther; 2019 Oct; 36(10):2910-2926. PubMed ID: 31401786
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
Ren H; Wang K; Yang H; Gao L
Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Poletti V; Ravaglia C; Tomassetti S
Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.
Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU
Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]